Linked prescribing and outcome data to find drug interactions with cancer therapy
Use joined-up pharmacy and hospital records to spot when a common everyday medicine makes a cancer drug work worse or cause more harm.
Interactions between anticancer agents and common co-medications (proton pump inhibitors with some kinase inhibitors and capecitabine; antibiotics and steroids with immunotherapy) have emerged from retrospective analyses years after approval. The proposal is a standing surveillance system using linked prescribing and outcome data that screens all new oncology drugs against the 200 most common co-medications, with signals triaged to confirmatory analysis or trials.
- Weak real-world evidence and registries · We do not reliably know what happens to patients after approval, so we cannot tell which drugs deliver in practice.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.
Pages like this
not linked directly; found by shared links- IdeaWearable activity data as a validated real-world endpoint
Shares Weak real-world evidence and registries, Real-world evidence, Toxicity and quality of life are undervalued.
- IdeaReal-world dose intensity and toxicity monitoring to revise labelled doses
Shares Weak real-world evidence and registries, Real-world evidence, Toxicity and quality of life are undervalued.
- IdeaNo mCODE, no payment: tie oncology reimbursement to a minimal structured record
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaGood practice standards and inspection for real-world data sources
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaOne international registry, not one per country, for conditional approvals
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaRequire genetic and target-trial evidence before funding any repurposing phase 3
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaAn automated pipeline emulating trials of every common drug against every cancer
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaOpen, benchmarked algorithms for lines of therapy and progression from routine data
Shares Weak real-world evidence and registries, Real-world evidence.